News & Presentations

UPCOMING EVENTS

Date	Title	Documents
January 13, 2020	Corporate Presentation – January	Add Files Corporate Presentation 1.7 MB
November 6, 2019	AR-13324-CS208 Japan Phase 2 Study Topline Results	Add Files AR-13324-CS208 Japan Phase 2 Study Topline Results 250.3 KB
November 6, 2019	Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST)	Add Files Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST) 450 KB

Date	Title and Summary	Additional Formats
Toggle SummaryOctober 22, 2009	Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study Novel Drug has Potential to Create Significant Improvement in Function of Diseased Tissue	View HTML Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study 22 KB
Toggle SummaryOctober 26, 2009	Biocentury - RhoKing Glaucoma	View HTML
Toggle SummaryMarch 7, 2011	Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio Financing Underscores Strong Clinical Progress and Positive Data in Lead Program	View HTML Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio 24 KB
Toggle SummaryApril 12, 2011	American Journal of Ophthalmology - Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension	View HTML